May 1, 2025
Riad Sherif, MD, discusses positive data from Oculis' phase 2 ACUITY trial of OCS-05 in acute optic neuritis, the significance this neuroprotective treatment will have for patients, and more.
Industry Insider: Oculis CEO Riad Sherif, MD